Foundayo is one of the newest names in UK weight management, and if you’ve been researching prescription weight loss options, you’ve probably seen it mentioned alongside Mounjaro and Wegovy. 

Unlike those, though, Foundayo is a tablet rather than an injection, which is a big part of why it’s attracting so much attention.

This guide explains what Foundayo is, how it works, who it’s suitable for, and what the evidence actually says about it, so you can have an informed conversation with a prescriber before deciding whether it’s right for you.

This article is for general information only and is not a substitute for a one-to-one consultation with a qualified prescriber. Foundayo is a prescription-only medicine and must only be used under proper medical supervision.

What Is Foundayo?

Foundayo is the UK brand name for orforglipron, a weight management and type 2 diabetes medicine made by Eli Lilly. It belongs to the same broad family of medicines as Mounjaro and Wegovy – GLP-1 receptor agonists – but with one key difference: it’s taken as a once-daily tablet rather than a weekly injection.

Foundayo was authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on 10 August 2026, making the UK the first country in Europe to approve this particular GLP-1 tablet for both weight management and glycaemic control in type 2 diabetes.

It’s also chemically different from other oral GLP-1 medicines already on the market, such as oral semaglutide (Wegovy tablets). Those are peptide-based, which means they’re broken down easily in the stomach and have to be taken on an empty stomach, with a small sip of water, followed by a 30-minute wait before eating or drinking anything else. 

Foundayo, by contrast, is a small-molecule GLP-1 agonist. It’s more stable in the digestive system, so it doesn’t come with those same fasting and timing restrictions – a genuinely practical difference for anyone who’s found those rules hard to work around.

How Does Foundayo Work?

Foundayo works in the same general way as other GLP-1 receptor agonists. It mimics a naturally occurring gut hormone (GLP-1) that plays a role in appetite and blood sugar regulation. In practical terms, this means it can help to:

  • Reduce appetite and hunger signals
  • Increase feelings of fullness after eating
  • Slow down gastric emptying, so food stays in the stomach for longer
  • Support more stable blood sugar levels

Combined with a reduced-calorie diet and increased physical activity, this is intended to support gradual, sustained weight loss, rather than acting as a stand-alone “fix”.

Who Can Take Foundayo?

Foundayo is licensed for adults who meet standard clinical criteria for weight management medication:

  • A body mass index (BMI) of 30 or above, or
  • A BMI of 27–30, together with at least one weight-related health condition, such as high blood pressure, high cholesterol, or prediabetes

Meeting these criteria is a starting point, not a guarantee of eligibility. A full online consultation with a UK-registered prescriber is needed to review your medical history, current medications, and overall suitability before any prescription is issued. 

Foundayo is not suitable for everyone, and safety always comes before availability.

Foundayo Dosing: How It’s Titrated

Foundayo is taken as a tablet, once a day, and the dose is increased gradually rather than starting at the full strength. 

This “titration” approach helps the body adjust and reduces the likelihood of side effects.

The licensed dosing schedule is:

  • 0.8mg (starting dose)
  • 2.5mg
  • 5.5mg
  • 9mg
  • 14.5mg
  • 17.2mg (highest licensed dose)

Patients typically stay on each dose for a minimum of one month before stepping up, and your prescriber will decide the right pace and ceiling dose for you based on how you respond and tolerate treatment. 

Not everyone needs to reach the highest dose to see results.

Because Foundayo doesn’t require fasting, it can generally be taken at a consistent time each day, with or without food. 

Your prescriber or the patient information leaflet will confirm the exact guidance for your dose.

How Effective Is Foundayo? What Does the Evidence Say?

The main evidence behind Foundayo comes from the ATTAIN-1 trial, a 72-week study involving more than 3,100 participants. 

In adults without type 2 diabetes taking the highest licensed dose (17.2mg), average weight loss was in the region of 11–12% of starting body weight, compared with roughly 2% in the group taking a placebo. 

(Reported figures vary slightly by source – Eli Lilly’s own patient information cites 11.1%, while UK pharmacy sources have cited 12.4% – see References below.)

A few things are worth keeping in mind when reading statistics like these:

  • These are average results across a large trial population – individual results vary considerably, and some people lose more, some less.
  • The figures reflect people who also followed a reduced-calorie diet and increased activity alongside the medication, not the tablet in isolation.
  • Improvements in cholesterol, blood pressure, and waist circumference were also observed during the trial, alongside weight loss.

No weight loss medication guarantees a specific result, and Foundayo should be considered one part of a broader, medically supervised weight management plan.

Foundayo vs Mounjaro, Wegovy and Orlistat

If you’re comparing your options, here’s a brief overview of how Foundayo differs from other treatments:

  • Foundayo (orforglipron) – once-daily oral tablet, small-molecule GLP-1, no fasting required.
  • Mounjaro (tirzepatide) – once-weekly injection, dual GIP/GLP-1 receptor agonist.
  • Wegovy (semaglutide) – available as both a once-weekly injection and an oral tablet; the oral form is peptide-based and requires fasting before and after taking it.
  • Orlistat – a different type of medicine entirely, taken with meals, which works by reducing the amount of dietary fat your body absorbs rather than acting on appetite hormones.

There isn’t a single “best” option. The right choice depends on your health history, how you feel about injections versus tablets, and what a prescriber advises after reviewing your circumstances. 

This is exactly the kind of decision worth talking through during your consultation.

Side Effects of Foundayo

As with other GLP-1 medicines, side effects are most common while your body adjusts to a new dose, and tend to ease over time.

Very common (affecting more than 1 in 10 people):

  • Nausea
  • Vomiting
  • Constipation
  • Diarrhoea
  • Indigestion
  • Abdominal pain

Common (affecting up to 1 in 10 people):

  • Dizziness
  • Headache
  • Increased heart rate
  • Low blood pressure
  • Bloating
  • Acid reflux
  • Hair thinning
  • Fatigue

This isn’t a complete list. 

Always read the patient information leaflet supplied with your medication, and speak to your prescriber or pharmacist if a side effect is severe, persistent, or worrying you. 

Side effects can also be reported directly to the MHRA via the Yellow Card Scheme.

Who Should Not Take Foundayo?

Foundayo isn’t suitable for everyone. You’re likely to be advised against taking it if you have:

  • A personal or family history of medullary thyroid carcinoma (a type of thyroid cancer), or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Severe liver impairment
  • Are pregnant, trying to conceive, or breastfeeding
  • A known allergy or hypersensitivity to orforglipron or any ingredient in the tablet

This is not an exhaustive list. A full medical history and current medication review, carried out during your consultation, is essential before Foundayo can be prescribed safely.

Is Foundayo Available on the NHS?

Not currently. Foundayo is only available in the UK through private prescription following a consultation. 

It is not yet routinely available on the NHS, as this depends on a separate evaluation by the National Institute for Health and Care Excellence (NICE). This may change in future, so it’s worth checking the latest position if NHS access is important to you.

How to Get Started With Foundayo

If you think Foundayo might be right for you, the process looks like this:

  • Complete an online consultation – a short questionnaire covering your health history, current medications, and weight loss goals.
  • Clinician review – one of our UK-registered prescribers reviews your answers to check the medication is safe and suitable for you.
  • Prescription and delivery – if approved, your medication is dispensed by our registered pharmacy and delivered discreetly.

Find more information on the Foundayo product page, or start your consultation to check your eligibility.

Frequently Asked Questions

Is Foundayo the same as Wegovy or Mounjaro? No. All three are weight management medicines, but Foundayo (orforglipron) is a different active ingredient to Wegovy (semaglutide) and Mounjaro (tirzepatide). Foundayo is also the only one of the three available exclusively as a tablet with no fasting requirement.

Do I need to fast before taking Foundayo? No. Because Foundayo is a small-molecule medicine rather than a peptide, it doesn’t require the fasting or “water-only” rules associated with some other oral GLP-1 tablets.

How much weight can I expect to lose on Foundayo? In clinical trials, adults on the highest dose lost an average of around 11–12% of their body weight over 72 weeks, alongside diet and lifestyle changes. Individual results vary, and this isn’t a guaranteed outcome.

Is Foundayo available on the NHS? Not currently. It’s available privately by prescription following a consultation, while NHS availability is considered separately by NICE.

What happens if I miss a dose? Missed-dose guidance depends on your specific dose and timing, and will be covered in your patient information leaflet and consultation. Speak to your prescriber or pharmacist if you’re unsure rather than doubling up on your own.

Can I take Foundayo alongside other medications? This depends entirely on your individual health history and current medications, which is exactly what your prescriber will assess during your consultation. Always disclose every medication and supplement you take, including over-the-counter products.

References

  1. GOV.UK / MHRA – UK first in Europe to authorise orforglipron for weight management and type 2 diabetes
  2. Eli Lilly – What Is Foundayo (orforglipron)
  3. MHRA Yellow Card Scheme – Report a side effect